Skip to main content
Industry News
Empagliflozin for heart failure fast-tracked by FDA

Boehringer Ingelheim and Eli Lilly's Jardiance, or empagliflozin, will undergo fast track review by the FDA as a medication to prevent hospitalization due to heart failure and also to lower the risk for all-cause mortality in adult patients with and without diabetes that have experienced a previous myocardial infarction.

Full Story: